Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Jiří MinaříkTomas PikaJakub RadochaAlexandra JungovaJan StraubTomas JelinekLudek PourPetr PavlicekMartin MistrikLucie BrozovaPetra KrhovskaKaterina MachalkovaPavel JindraIvan SpickaHana PlonkovaMartin StorkJaroslav BacovskyLenka CapkovaMichal SykoraPetr KesslerLukas StejskalAdriana HeindorferJana UllrychovaTomas SkacelVladimir MaisnarRoman HajekPublished in: BMC cancer (2021)
Our analysis confirms the results of the TOURMALINE-MM1 study and shows benefit of all-oral triplet IRD treatment versus RD doublet. It demonstrates that the addition of ixazomib to RD improves key survival endpoints in patients with RRMM in a routine clinical setting.
Keyphrases
- multiple myeloma
- clinical practice
- newly diagnosed
- end stage renal disease
- low dose
- ejection fraction
- high dose
- chronic kidney disease
- acute lymphoblastic leukemia
- acute myeloid leukemia
- prognostic factors
- peritoneal dialysis
- stem cell transplantation
- free survival
- patient reported outcomes
- diffuse large b cell lymphoma
- combination therapy